Ascendis Pharma A (ASND) Gross Margin (2021 - 2026)

Ascendis Pharma A (ASND) has 6 years of Gross Margin data on file, last reported at 92.9% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 1025.0% year-over-year to 92.9%; the trailing twelve-month figure through Mar 2026 stood at 74.51% (up 1221.0% YoY), and the FY2025 full-year result was 86.82%, down 190.0% from the prior year.
• Gross Margin advanced to 92.9% in Q1 2026, from 53.76% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 92.9% in Q1 2026 to a low of 37.81% in Q1 2022.
• A 5-year average of 74.17% and a median of 80.63% in 2024 frame the typical range for Gross Margin.
• Peak annual rise in Gross Margin reached 7608 bps in 2022, while the deepest fall reached 6219 bps in 2022.
• Tracing ASND's Gross Margin over 5 years: stood at 77.68% in 2022, then tumbled by 50 bps to 39.06% in 2023, then jumped by 32 bps to 51.58% in 2024, then rose by 4 bps to 53.76% in 2025, then jumped by 73 bps to 92.9% in 2026.
• Business Quant data shows ASND's Gross Margin at 92.9% in Q1 2026, 53.76% in Q4 2025, and 89.54% in Q3 2025.